INM: financial statements from SEC — TradeAlmanac

INM

InMed Pharmaceuticals Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Jun 30, 2025	Jun 30, 2024
Revenue	5m	5m
Cost of revenue	3m	3m
Gross profit	2m	1m
Research and development	3m	3m
Selling, general and administrative	7m	6m
Operating expenses	10m	9m
Pre-tax income	−8m	−8m
Income tax	—	7,100
Net income	−8m	−8m
Earnings per share	−8.36	−20.14
Earnings per share, diluted	−8.36	−20.14
Weighted average shares	975,985	381,053
Weighted average shares, diluted	975,985	381,053

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	5m	7m	9m	11m	5m	3m	6m	7m
Short-term investments	41,625	42,675

Cash flow

Metric	Jun 30, 2025	Jun 30, 2024
Operating cash flow	−8m	−7m
Depreciation and amortisation	212,839	219,600
Share-based compensation	119,307	137,714
Capital expenditure	—	9,293
Investing cash flow	—	−9,293
Financing cash flow

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)